# US Post Traumatic Stress Disorder Market > US Post Traumatic Stress Disorder Market Research Report: Size, Share, Trend Analysis By Treatment (Prazosin, Anti-anxiety Medications, Psychotherapy, Medications, Others) and By End Userss (Ambulatory Surgical Centers, Hospitals & Clinics) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 5.88% - **2024:** $ 4,000 Million - **2025:** $ 4,235.2 Million - **2035:** $ 7,500 Million - **Key Players:** Pfizer Inc (US), Johnson & Johnson (US), Eli Lilly and Company (US), AstraZeneca PLC (GB), Boehringer Ingelheim GmbH (DE), Novartis AG (CH), Otsuka Pharmaceutical Co Ltd (JP), H. Lundbeck A/S (DK), Teva Pharmaceutical Industries Ltd (IL) **Report ID:** MRFR/HC/16112-HCR · **Pages:** 100 · **Author:** Rahul Gotadki & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-post-traumatic-stress-disorder-market-17640 --- ## Market Summary ## **US Post Traumatic Stress Disorder Market Overview** As per MRFR analysis, the US Post Traumatic Stress Disorder Market Size was estimated at 3.7 (USD Billion) in 2023. The US Post Traumatic Stress Disorder Market Industry is expected to grow from 4(USD Billion) in 2024 to 7 (USD Billion) by 2035. The US Post Traumatic Stress Disorder Market CAGR (growth rate) is expected to be around 5.219% during the forecast period (2025 - 2035). ### **Key Market Trends Highlighted** The US Post Traumatic Stress Disorder (PTSD) market is experiencing significant growth driven by increased awareness and diagnosis of the condition. This rise is largely attributed to the growing number of veterans and active military personnel suffering from PTSD due to combat exposure, as highlighted in reports from the Department of Veterans Affairs. Furthermore, a surge in mental health awareness among the general population has led to higher demand for effective treatment options, including therapy and medication. In recent years, there has been a notable trend towards the development of innovative therapies, such as digital therapeutic solutions and telehealth options, providing patients greater access to care. The COVID-19 pandemic has also accelerated the adoption of teletherapy, making mental health services more accessible to those in need. Additionally, a greater focus on personalized medicine is emerging in the PTSD market, with treatments being tailored to the individual needs of patients based on their psychological profiles. There are ample opportunities to be explored within the US PTSD market. The combination of advancing technology and increasing investment in mental health services presents a chance for new entrants and startups to innovate within this space. Furthermore, partnerships between tech companies and mental health professionals can lead to improved treatment modalities, enhancing patient outcomes. Efforts to destigmatize mental health issues are also creating a favorable environment for the expansion of PTSD-related services, as more individuals feel comfortable seeking help. Overall, these trends indicate a forward momentum in addressing the challenges of PTSD in the US, which is crucial for enhancing the quality of life for affected individuals. Source: Primary Research, Secondary Research, MRFR Database and Analyst Review ## **US Post Traumatic Stress Disorder Market Drivers** ### **Rising Awareness of Post Traumatic Stress Disorder in the US** In recent years, there has been a significant increase in the awareness and understanding of Post Traumatic Stress Disorder (PTSD) in the United States. Organizations such as the Department of Veterans Affairs have implemented various awareness campaigns to educate the public and healthcare professionals about PTSD. According to a report from the National Institute of Mental Health, approximately 8 million adults in the US experience PTSD annually. The increase in awareness leads to more individuals seeking treatment, contributing to the growth of the US Post Traumatic Stress Disorder Market Industry. As public knowledge expands, it is estimated that healthcare systems will see a rise in patients seeking therapeutic interventions, thus boosting market demand for effective PTSD treatments and support services. ### **Government Initiatives and Funding for Mental Health Services** The US government has made considerable strides in enhancing funding and initiatives for mental health services, particularly for PTSD. In 2021, the American Rescue Plan provided significant mental health funding, including resources specifically earmarked for PTSD treatment for veterans. According to the Substance Abuse and Mental Health Services Administration, there has been a budget increase of 10% annually for mental health services in recent years. This substantial investment is aimed at improving access to treatment options and support services, such as counseling and therapy, directly benefiting the US Post Traumatic Stress Disorder Market Industry. This strong governmental support is expected to cultivate an environment conducive to market growth. ### **Increasing Incidence of Trauma-Related Incidents** The prevalence of trauma-related incidents such as natural disasters, mass shootings, and military engagements has surged in the US, leading to a corresponding rise in Post Traumatic Stress Disorder cases. The Centers for Disease Control and Prevention reported that approximately 1 in 3 individuals exposed to trauma develop PTSD within the first year after the incident. This statistic underscores a growing concern as more people experience significant traumatic events, thereby increasing the demand for interventions within the US Post Traumatic Stress Disorder Market Industry. Addressing the psychological impacts of trauma in the aftermath of these events will drive innovation and growth within the market. ### **Advancements in Treatment Options for PTSD** There has been substantial innovation in the treatment options available for Post Traumatic Stress Disorder in the United States, which is a key driver for the market. Emerging research and technology have led to the development of new therapeutic approaches, such as Eye Movement Desensitization and Reprocessing (EMDR) and virtual reality therapy, showing promise in effectively treating PTSD. The American Psychiatric Association has highlighted improved efficacy rates in patients receiving these modern treatments. In response to these advancements, healthcare providers are increasingly integrating evidence-based therapies into their services, fostering growth in the US Post Traumatic Stress Disorder Market Industry. With a projected increase in the adoption of advanced treatment methods, the overall market is expected to benefit substantially. ## **US Post Traumatic Stress Disorder Market Segment Insights** ### **Post Traumatic Stress Disorder Market Treatment Insights** The Treatment segment of the US [**Post Traumatic Stress Disorder Market**](../../../reports/post-traumatic-stress-disorder-market-8376)has been evolving rapidly as mental health awareness continues to grow within the United States. With research and clinical advancements, an increasing number of therapies and medications are now available to address the diverse needs of PTSD patients. Treatment approaches can be broadly categorized into medications and psychosocial therapies. Medications such as Prazosin have gained recognition for their efficacy in alleviating nightmares, a common symptom of PTSD. This medicine, in conjunction with anti-anxiety medications, represents a significant component of pharmacotherapy, offering crucial support in managing anxiety levels associated with traumatic stress. Psychotherapy has also proven essential in the treatment of PTSD, employing evidence-based techniques such as Cognitive Behavioral Therapy (CBT) which has shown considerable success. In the US, the emphasis on such therapeutic interventions stems from the clinical understanding that many individuals suffering from PTSD benefit substantially from therapy tailored to their specific experiences and symptoms. In addition, various other treatment modalities are emerging, contributing to the comprehensive care available for individuals with PTSD. This expanding range of options caters to different preferences and clinical needs, allowing for a more personalized approach to treatment, which enhances patient engagement and overall outcomes. Moreover, the stigma surrounding mental health issues like PTSD is gradually diminishing in the US, encouraging more individuals to pursue treatment. This cultural shift, combined with an increase in funding and resources for mental health services, is positively impacting the accessibility and effectiveness of interventions. In this context, the Treatment segment is characterized by distinct dynamics, where ongoing research and development are set to propel advancements further. Collectively, these aspects reflect a promising landscape for the Treatment segment of the US Post Traumatic Stress Disorder Market, with the potential for positive societal impact by improving the quality of life for affected individuals. Source: Primary Research, Secondary Research, MRFR Database and Analyst Review ### **Post Traumatic Stress Disorder Market End Users Insights** The End Users segment of the US Post Traumatic Stress Disorder Market encompasses vital healthcare facilities such as Ambulatory Surgical Centers, Hospitals, and Clinics, which play a crucial role in delivering care to individuals affected by PTSD. Hospitals are typically the primary point of contact for patients requiring comprehensive assessment, treatment, and ongoing mental health services, thereby significantly contributing to patient recovery and well-being. Clinics offer specialized outpatient care, focusing on therapy and counseling, which can be critical for long-term management of PTSD. Ambulatory Surgical Centers serve as important facilities for outpatient procedures, facilitating specialized treatments that can enhance patient access to care. The growing awareness of mental health issues, coupled with the increasing prevalence of PTSD among various demographics, particularly veterans and first responders, underscores the importance of these End Users in addressing the mental health crisis in the US. Furthermore, initiatives by government organizations to improve mental health services and reduce stigma related to PTSD are expected to drive growth and innovation within these facilities. The increasing demand for integrated care approaches that combine various treatment modalities further emphasizes the significance of this segment in enhancing patient outcomes and supporting the overall US Post Traumatic Stress Disorder Market. ## **US Post Traumatic Stress Disorder Market Key Players and Competitive Insights** The US Post Traumatic Stress Disorder Market is characterized by a complex landscape of stakeholders, including pharmaceutical companies, healthcare providers, and various non-profit organizations, each vying for a share of the market dedicated to the diagnosis and treatment of PTSD. This market has been experiencing a surge in attention due to the growing prevalence of PTSD among various populations, including veterans, first responders, and other trauma survivors. As awareness and understanding of PTSD expand, there is an increasing demand for innovative therapies, diagnostic tools, and comprehensive support systems. Competitive insights into this market reveal a race among several prominent pharmaceutical players to capture market share through research, development, strategic partnerships, and marketing efforts, while addressing the specific needs of patients and healthcare systems in the US. ### **Key Player Analysi** AstraZeneca has established a significant presence in the US Post Traumatic Stress Disorder Market, showcasing its commitment to developing effective treatment options for psychological trauma-related conditions. The company has a robust pipeline focusing on mental health interventions, supported by substantial investment in research and development. AstraZeneca's strengths lie in its innovative approach to drug discovery and a strong operational base that enables efficient delivery of treatments. Its experience in handling large-scale clinical trials has helped the company understand the unique challenges faced by PTSD patients and tailor its solutions effectively. Furthermore, AstraZeneca's strategic collaborations with academic institutions allow for enhanced understanding and innovative treatment methodologies that create a competitive edge in this market, making it well-positioned to meet the evolving needs of patients and healthcare providers in the United States. Similarly, Novartis plays a crucial role in the US Post Traumatic Stress Disorder Market, with a portfolio that includes key pharmaceuticals addressing mental health issues. The company emphasizes research and innovation, aiming to provide transformative therapies that enhance the quality of life for individuals battling PTSD. Novartis has made strategic moves, including mergers and acquisitions, aimed at expanding its therapeutic capabilities and speeding up the development of targeted treatments. Through its strong brand presence and initiatives to engage with healthcare professionals, Novartis remains a vital player in shaping the dialogue surrounding PTSD treatments. Its strengths within the US market include an established distribution network and a reputation for delivering reliable and effective therapies, positioning the company favorably against competitors. The emphasis on patient-centric approaches further solidifies Novartis’s role within this sector, ensuring that developments in PTSD treatment align with patient needs and regulatory standards. ## **Key Companies in the US Post Traumatic Stress Disorder Market Include** ## **US Post Traumatic Stress Disorder Market Industry Developments** The US Post Traumatic Stress Disorder Market has seen significant developments recently, particularly in the realm of drug approvals and interventions. Key pharmaceutical companies such as Eli Lilly and Pfizer have been advancing their research efforts on novel therapies aimed at PTSD. In September 2023, a notable increase in market valuation was observed, driven largely by heightened funding for Research and Development efforts in mental health, particularly targeting PTSD among veterans and first responders. Major companies, including AstraZeneca and Novartis, are actively collaborating on clinical trials to evaluate the effectiveness of emerging treatments, reflecting a growing commitment to addressing PTSD on a larger scale. In terms of mergers and acquisitions, recent activities have involved strategic alliances by companies like Merck and Roche, focusing on expanding their portfolios to include innovative PTSD therapies. Over the last 2-3 years, the market has witnessed a surge in attention from both public and private sectors, with initiatives aimed at reducing the stigma associated with mental health and increasing accessibility to treatment options. These developments indicate a robust and evolving landscape for PTSD management in the US, supported by significant investments and collaborative efforts among leading pharmaceutical companies. ## **US Post Traumatic Stress Disorder Market Segmentation Insights** ### **Post Traumatic Stress Disorder Market Treatment Outlook** ### **Post Traumatic Stress Disorder Market End Users Outlook** ## Market Drivers ### Rising Incidence of PTSD Cases The post traumatic-stress-disorder market is experiencing growth due to the increasing incidence of PTSD cases in the US. Recent studies indicate that approximately 7-8% of the population will experience PTSD at some point in their lives. This prevalence drives demand for effective treatment options, including therapy and medication. The market is projected to expand as more individuals seek help, leading to a potential increase in market value by over $3 billion by 2027. The rising awareness of mental health issues contributes to this trend, as more people recognize the symptoms and seek professional assistance. Consequently, healthcare providers are focusing on developing specialized programs to address the needs of PTSD patients, further propelling the post traumatic-stress-disorder market forward. ### Government Initiatives and Funding Government initiatives aimed at addressing mental health issues significantly impact the post traumatic-stress-disorder market. In recent years, federal and state governments have allocated substantial funding to mental health programs, including those specifically targeting PTSD. For instance, the Department of Veterans Affairs has increased its budget for mental health services, recognizing the high prevalence of PTSD among veterans. This funding not only enhances access to treatment but also encourages research into innovative therapies. As a result, the post traumatic-stress-disorder market is likely to benefit from improved treatment options and increased patient engagement, potentially leading to a market growth rate of around 5% annually over the next few years. ### Growing Public Awareness Campaigns Public awareness campaigns aimed at educating individuals about PTSD are playing a crucial role in shaping the post traumatic-stress-disorder market. Organizations and advocacy groups are actively working to reduce stigma and promote understanding of PTSD symptoms and treatment options. These campaigns often utilize social media, community events, and educational resources to reach a broader audience. As awareness increases, more individuals are likely to seek help, leading to a higher demand for PTSD-related services. This trend suggests a potential market growth of approximately 8% as public perception shifts and more people recognize the importance of addressing mental health issues, thereby positively impacting the post traumatic-stress-disorder market. ### Advancements in Therapeutic Approaches The post traumatic-stress-disorder market is witnessing advancements in therapeutic approaches, which are reshaping treatment paradigms. Innovative therapies, such as Eye Movement Desensitization and Reprocessing (EMDR) and cognitive-behavioral therapy (CBT), have shown promising results in alleviating PTSD symptoms. Additionally, the integration of virtual reality (VR) technology in exposure therapy is gaining traction, providing immersive experiences that help patients confront their traumas in a controlled environment. These advancements not only enhance treatment efficacy but also attract investment from pharmaceutical companies and healthcare providers. As a result, the post traumatic-stress-disorder market is expected to grow, with a projected increase in the adoption of these therapies by approximately 15% over the next five years. ### Increased Focus on Mental Health in Workplaces The growing emphasis on mental health in workplaces is influencing the post traumatic-stress-disorder market. Employers are increasingly recognizing the importance of mental well-being for productivity and employee satisfaction. Consequently, many organizations are implementing mental health programs that include PTSD awareness and support. This trend is particularly evident in high-stress industries, where employees may be more susceptible to trauma. As companies invest in mental health resources, the demand for PTSD treatment options is likely to rise. This shift could lead to a market expansion of around 10% as more individuals seek assistance through employer-sponsored programs, thereby enhancing the overall landscape of the post traumatic-stress-disorder market. ## Future Outlook The [Post Traumatic Stress Disorder Market](https://www.marketresearchfuture.com/reports/post-traumatic-stress-disorder-market-8376) is projected to grow at a 5.88% CAGR from 2025 to 2035, driven by increased awareness, innovative therapies, and expanding treatment options. **New opportunities:** - Development of telehealth platforms for remote therapy sessions. Investment in AI-driven diagnostic tools for early detection. Expansion of personalized treatment plans based on genetic profiling. By 2035, the market is expected to achieve substantial growth, reflecting evolving treatment paradigms. ## Segment Insights ### By Treatment: Prazosin (Largest) vs. Psychotherapy (Fastest-Growing) In the US post traumatic-stress-disorder market, the treatment landscape is primarily dominated by medications such as Prazosin and various anti-anxiety medications. Prazosin is recognized for its role in alleviating nightmares associated with PTSD, claiming a substantial market share. This dominance can be attributed to its established efficacy and favorable safety profile, making it a preferred choice among healthcare providers. Conversely, the increasing acceptance and integration of psychotherapy, specifically cognitive behavioral therapies, are driving its rapid growth within the market. As awareness of mental health and the benefits of therapeutic interventions rise, psychotherapy is emerging as a significant treatment modality. This shift reflects changing attitudes towards mental health, advocating for holistic approaches alongside pharmacological treatments. Prazosin (Dominant) vs. Psychotherapy (Emerging) Prazosin, recognized as a dominant player in the treatment of PTSD, works effectively to minimize traumatic stress reactions, particularly nightmares. It has gained a strong foothold due to its clinical efficacy and safety, becoming a first-line defense for many patients. In contrast, psychotherapy, specifically various forms of talk therapy, is emerging rapidly within the market as an essential complement to medication. Its growth is fueled by increasing demand for comprehensive treatment strategies that address both the psychological and physiological aspects of PTSD. As healthcare providers and patients alike recognize the importance of mental well-being, psychotherapy is expected to see expanding applications, further establishing its role in effective PTSD management. ### By End-User: Ambulatory Surgical Centers (Largest) vs. Hospitals and Clinics (Fastest-Growing) Market share in the segment of US post traumatic-stress-disorder is primarily dominated by Ambulatory Surgical Centers, which hold a significant portion of the market due to their ability to provide specialized care and therapy in a less intensive setting. Hospitals and Clinics, while still an essential part of the market, capture a smaller segment as they often deal with a broader range of medical issues, resulting in less focused PTSD treatment options. Growth trends indicate a healthy increase in the demand for both Ambulatory Surgical Centers and Hospitals and Clinics. Factors driving the expansion include a rising awareness of mental health, increased funding for PTSD treatment, and the preference for outpatient care. The shifting mindset towards mental health care encourages the establishment of more dedicated centers, while hospitals and clinics adapt to the growing need for specialized support, particularly in urban areas. Ambulatory Surgical Centers (Dominant) vs. Hospitals and Clinics (Emerging) Ambulatory Surgical Centers are recognized as dominant players in the treatment of post traumatic-stress-disorder due to their efficient and patient-centric approach, which allows for personalized treatment plans that cater specifically to individuals experiencing PTSD. This segment benefits from lower waiting times and tailored therapies that enhance recovery outcomes. Conversely, Hospitals and Clinics are emerging as important entities in this landscape, adjusting their services to include specialized PTSD treatments. These facilities often provide comprehensive care, albeit with a broader focus, which may limit their ability to deliver specialized PTSD interventions as effectively as dedicated centers. However, their large infrastructure offers significant resources and potential partnerships to improve PTSD service delivery. ## Competitive Benchmarking The post traumatic-stress-disorder market is characterized by a complex competitive landscape, driven by increasing awareness of mental health issues and the growing demand for effective treatment options. Key players such as Pfizer Inc (US), Johnson & Johnson (US), and Eli Lilly and Company (US) are actively engaged in this market, each adopting distinct strategies to enhance their market presence. Pfizer Inc (US) focuses on innovation through the development of novel therapeutics, while Johnson & Johnson (US) emphasizes strategic partnerships to expand its product offerings. Eli Lilly and Company (US) is investing in digital health solutions to improve patient engagement and treatment adherence, collectively shaping a competitive environment that prioritizes innovation and patient-centric approaches.The market structure appears moderately fragmented, with several players vying for market share. Key business tactics include localizing manufacturing to reduce costs and optimize supply chains, which enhances operational efficiency. The collective influence of these major companies fosters a dynamic environment where competition is not solely based on pricing but also on the quality and efficacy of treatment options. In October Pfizer Inc (US) announced a collaboration with a leading digital health company to integrate AI-driven analytics into its PTSD treatment protocols. This strategic move is likely to enhance patient outcomes by providing personalized treatment plans, thereby positioning Pfizer as a leader in innovative therapeutic solutions. The integration of technology into treatment regimens may also serve to attract a broader patient base, reflecting a shift towards more tailored healthcare solutions. In September Johnson & Johnson (US) launched a new initiative aimed at increasing access to mental health resources in underserved communities. This initiative underscores the company's commitment to social responsibility and aligns with current trends emphasizing equity in healthcare. By addressing disparities in access, Johnson & Johnson not only enhances its brand reputation but also potentially expands its market reach, tapping into a demographic that has historically been underserved. In August Eli Lilly and Company (US) unveiled a new digital platform designed to support PTSD patients through telehealth services. This platform is indicative of the growing trend towards digitalization in healthcare, allowing for greater flexibility and accessibility in treatment. By leveraging technology, Eli Lilly aims to improve patient engagement and adherence to treatment protocols, which could lead to better health outcomes and increased patient satisfaction. As of November current competitive trends in the post traumatic-stress-disorder market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances among key players are shaping the landscape, fostering innovation and enhancing treatment efficacy. The competitive differentiation is likely to evolve, moving away from traditional price-based competition towards a focus on technological advancements, innovative treatment solutions, and reliable supply chains. This shift suggests that companies prioritizing these aspects will be better positioned to thrive in an increasingly complex market. ## Recent News & Developments The US Post Traumatic Stress Disorder Market has seen significant developments recently, particularly in the realm of drug approvals and interventions. Key pharmaceutical companies such as Eli Lilly and Pfizer have been advancing their research efforts on novel therapies aimed at PTSD. In September 2023, a notable increase in market valuation was observed, driven largely by heightened funding for Research and Development efforts in mental health, particularly targeting PTSD among veterans and first responders. Major companies, including AstraZeneca and Novartis, are actively collaborating on clinical trials to evaluate the effectiveness of emerging treatments, reflecting a growing commitment to addressing PTSD on a larger scale. In terms of mergers and acquisitions, recent activities have involved strategic alliances by companies like Merck and Roche, focusing on expanding their portfolios to include innovative PTSD therapies. Over the last 2-3 years, the market has witnessed a surge in attention from both public and private sectors, with initiatives aimed at reducing the stigma associated with mental health and increasing accessibility to treatment options. These developments indicate a robust and evolving landscape for PTSD management in the US, supported by significant investments and collaborative efforts among leading pharmaceutical companies. ## Report Scope | MARKET SIZE 2024 | 4000.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 4235.2(USD Million) | | MARKET SIZE 2035 | 7500.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.88% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Pfizer Inc (US), Johnson & Johnson (US), Eli Lilly and Company (US), AstraZeneca PLC (GB), Boehringer Ingelheim GmbH (DE), Novartis AG (CH), Otsuka Pharmaceutical Co Ltd (JP), H. Lundbeck A/S (DK), Teva Pharmaceutical Industries Ltd (IL) | | Segments Covered | Treatment, End-User | | Key Market Opportunities | Integration of digital therapeutics and telehealth solutions in the post traumatic-stress-disorder market. | | Key Market Dynamics | Rising demand for innovative therapies drives competition and regulatory scrutiny in the post traumatic-stress-disorder market. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the overall market valuation of the US post traumatic-stress-disorder market in 2024?** A: The overall market valuation was $4000.0 Million in 2024. **Q: What is the projected market valuation for the US post traumatic-stress-disorder market by 2035?** A: The projected valuation for 2035 is $7500.0 Million. **Q: What is the expected CAGR for the US post traumatic-stress-disorder market during the forecast period 2025 - 2035?** A: The expected CAGR during the forecast period 2025 - 2035 is 5.88%. **Q: Which companies are considered key players in the US post traumatic-stress-disorder market?** A: Key players include Pfizer Inc, Johnson & Johnson, Eli Lilly and Company, and AstraZeneca PLC. **Q: What are the major treatment segments in the US post traumatic-stress-disorder market?** A: Major treatment segments include Psychotherapy, Medications, and Anti-anxiety Medications. **Q: What was the valuation range for Psychotherapy in the US post traumatic-stress-disorder market?** A: The valuation range for Psychotherapy was $1200.0 Million to $2500.0 Million. **Q: What is the valuation range for Anti-anxiety Medications in the market?** A: The valuation range for Anti-anxiety Medications is $600.0 Million to $1200.0 Million. **Q: What are the end-user segments in the US post traumatic-stress-disorder market?** A: End-user segments include Hospitals and Clinics, and Ambulatory Surgical Centers. **Q: What was the valuation range for Hospitals and Clinics in 2024?** A: The valuation range for Hospitals and Clinics was $2800.0 Million to $5250.0 Million. **Q: What is the projected growth trend for the US post traumatic-stress-disorder market?** A: The market is expected to grow from $4000.0 Million in 2024 to $7500.0 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-post-traumatic-stress-disorder-market-17640*